NCT02851342View on ClinicalTrials.gov

GTA-MEG as a Biomarker for Cognition in MS

CompletedOBSERVATIONAL

Enrollment

159

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2019

Conditions

Multiple Sclerosis

Trial Locations (1)

1820

National MS Center Melsbroek, Melsbroek

All Listed Sponsors

lead

Universitair Ziekenhuis Brussel

OTHER

NCT02851342 - GTA-MEG as a Biomarker for Cognition in MS | Biotech Hunter | Biotech Hunter